A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
Sponsor: DeNova Research
Listed as NCT01614743, this PHASE2 trial focuses on Rosacea and remains completed. Sponsored by DeNova Research, it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Oct 2020 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- DeNova Research
- Merz North America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .